[1] Ghany MG,Strader DB,Thomas DL,et al. Diagnosis,management,and treatment of hepatits C:an update. Hepatology,2009,49(4):1335-1374. [2] 中华医学会肝病学分会和传染病与寄生虫病学分会.丙型肝炎防治指南. 中华肝脏病杂志,2004,12(4):194-198. [3] Lu L,Nakano T,He Y,et al. Hepatitis C virus genotype distribution in China:predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol,2005,75(4):538-549. [4] 刘斌,王宇明,谭朝霞. 重庆地区69例丙型肝炎病毒感染基因分型研究. 重庆医学,2002,31(3):174-175. [5] 雷华,刘俊,庄林,等. 昆明地区丙型肝炎基因型的分析.肝脏,2010,15(3):193-194. [6] 谢尧,徐道振,陆志檬,等. HCV基因型对慢性丙型肝炎干扰素疗效的影响. 中华肝脏病杂志,2004,12(2):72-75. [7] 于建武,孙丽杰,李晓光,等. 快速和早期病毒学应答对慢性丙型肝炎患者持续病毒学应答的预测价值.中华传染病杂志,2008,26(1):36-39. [8] Jacobson IM,Brown RS Jr,Freilich B,et al. Peginterferon alfa-2b and weight-based or flat- dose ribavirin in chronic hepatitis C patients:a randomized trial. Hepatology,2007,46(4):953-956. [9] Fried MW,Hadziyannis SJ,Shiffman M,et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol,2011,55(1):69-75. [10] Mangia A,Santoro R,Minerva N,et al. Peginterferon alfa-2b and ribavirin for 12 vs.24 weeks in HCV genotype 2 or 3. N Engl J Med,2005,352(25):2609-2617. |